Stay updated with breaking news from Priority Medicine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy Expected in mid-2024, a Global...
After 48 weeks of treatment with survodutide, patients demonstrated histological improvement, a reduction in liver fat content, and did not experience worsening fibrosis.
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company...
SHANGHAI, Dec. 4, 2023 /PRNewswire/ -- On 4 Dec. 2023, Abbisko Therapeutics announced that it has entered into a licensing agreement with Merck, a leading science and technology company headquartered in Darmstadt, Germany. Under the terms of the agreement, Merck will be granted an exclusive license to commercialize products comprising or containing pimicotinib (ABSK021) for all indications in Chinese...
13.11.2023 - Company Prioritizes Greatest Near-term Value-Driving Programs: ANX005 for Guillain-Barré Syndrome (GBS), ANX007 for Geographic Atrophy (GA) and First-in-Kind Complement Small Molecule, ANX1502 ANX005 Phase 3 Pivotal Data in GBS On Track for ...